[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
INTRODUCTION: The optimal management of prostate cancer patients with lymph node metastasis remains controversial. In this article, the outcome in a consecutive group of patients with newly diagnosed lymph node positive prostate cancer is presented. MATERIALS AND METHODS: In 59 patients with histological verified lymph node positive disease but without osseous metastasis, outcome is described by time to biochemical progression, time to metastasis and survival. RESULTS: Median age at diagnosis was 62 years. Median pre-treatment PSA was 21 ng/ml. Endocrine treatment was initiated within median 2 weeks in 97% of the patients. Median follow-up was 3 years. Median time to biochemical progression was 1.8 years and 5-year biochemical recurrence-free survival was 14%. Median time to development of osseous metastasis was 4.4 years and 5-year metastasis-free survival was 49%. Eighteen of the 59 patients died during follow-up, 15 deaths were attributable to prostate cancer. Estimated median survival was 5.5 years. CONCLUSION: Despite early androgen deprivation therapy, patients with lymph node positive prostate cancer have a grave prognosis with a high risk of progression and disease-specific mortality
Udgivelsesdato: 2008/8/18
Udgivelsesdato: 2008/8/18
Originalsprog | Dansk |
---|---|
Tidsskrift | Ugeskrift for læger |
Vol/bind | 170 |
Udgave nummer | 34 |
Sider (fra-til) | 2554-2558 |
Antal sider | 4 |
ISSN | 0041-5782 |
Status | Udgivet - 2008 |
ID: 14276211